Related Experiment Video
Updated: Jul 5, 2025

Antimicrobial Peptides Produced by Selective Pressure Incorporation of Non-canonical Amino Acids
Published on: May 4, 2018
LL-37_Renalexin hybrid peptide exhibits antimicrobial activity at lower MICs than its counterpart single peptides
Julius Kwesi Narh1, Nestor G Casillas-Vega2, Xristo Zarate3
1Facultad de Ciencias Quimicas, Universidad Autonoma de Nuevo Leon, Avenida Universidad s/n, Ciudad Universitaria, 66455, San Nicolas de los Garza, NL, Mexico.
Abstract:
An alarming global public health and economic peril has been the emergence of antibiotic resistance resulting from clinically relevant bacteria pathogens, including Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species constantly exhibiting intrinsic and extrinsic resistance mechanisms against last-resort antibiotics like gentamycin, ciprofloxacin, tetracycline, colistin, and standard ampicillin prescription in clinical practices. The discovery and applications of antimicrobial peptides (AMPs) with antibacterial properties have been considered and proven as alternative antimicrobial agents to antibiotics. In this study, we have designed, produced, and purified a recombinant novel multifunctional hybrid antimicrobial peptide LL-37_Renalexin for the first time via the application of newly designed flexible GS peptide linker coupled with the use of our previously characterized small metal-binding proteins SmbP and CusF3H+ as carrier proteins that allow for an enhanced bacterial expression, using BL21(DE3) and SHuffle T7(DE3) Escherichia coli strains, and purification of the hybrid peptide via immobilized metal affinity chromatography. The purified tag-free LL-37_Renalexin hybrid peptide exhibited above 85% reduction in bacteria colony-forming units and broad-spectrum antimicrobial effects against Staphylococcus aureus, Escherichia coli, Methicillin-resistant Staphylococcus aureus (MRSA), and Klebsiella pneumoniae bacteria clinical isolates at a lower minimum inhibition concentration level (10-33 microM) as compared to its counterpart single-AMPs LL-37 and Renalexin (50-100 microM). KEY POINTS: • The hybrid antimicrobial peptide LL-37_Renalexin has been designed using a GS linker. • The peptide was expressed with the carrier proteins SmbP and CusF3H+. • The hybrid peptide shows antibacterial potency against clinical bacterial isolates.
Insights
A new hybrid antimicrobial peptide, LL-37_Renalexin, was developed to combat antibiotic resistance. This novel peptide shows broad-spectrum antibacterial activity against resistant bacteria at lower concentrations than existing agents.
Area of Science:
- Biochemistry
- Microbiology
- Drug Discovery
Background:
- Antibiotic resistance is a major global health threat, necessitating novel therapeutic strategies.
- Antimicrobial peptides (AMPs) are promising alternatives to conventional antibiotics due to their antibacterial properties.
Purpose of the Study:
- To design, produce, and purify a novel multifunctional hybrid antimicrobial peptide, LL-37_Renalexin.
- To evaluate the antibacterial efficacy of LL-37_Renalexin against clinically relevant bacterial pathogens.
Main Methods:
- A hybrid peptide (LL-37_Renalexin) was constructed using a GS linker and carrier proteins (SmbP, CusF3H+).
- Recombinant expression was achieved in Escherichia coli strains (BL21(DE3), SHuffle T7(DE3)).
- Purification was performed using immobilized metal affinity chromatography.
Main Results:
- The purified tag-free LL-37_Renalexin demonstrated over 85% reduction in bacterial colony-forming units.
- Broad-spectrum antimicrobial activity was observed against Staphylococcus aureus, Escherichia coli, MRSA, and Klebsiella pneumoniae.
- LL-37_Renalexin exhibited lower minimum inhibitory concentrations (10-33 µM) compared to single AMPs (50-100 µM).
Conclusions:
- The novel hybrid antimicrobial peptide LL-37_Renalexin is effectively expressed and purified.
- LL-37_Renalexin displays potent broad-spectrum antibacterial activity against clinical isolates.
- This hybrid peptide represents a promising therapeutic candidate for combating antibiotic-resistant bacteria.
More Related Videos
12:02An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
Published on: November 2, 2016
06:18A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
Published on: March 3, 2023
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...